Showing 1 - 3 results of 3 for search 'Klaus P. Hoeflich', query time: 0.02s Refine Results
  1. 1
    Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

    Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. by Bijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin, Jeffrey Eastham-Anderson, James E Cupp, Yuxin Liang, David P Davis, Klaus P Hoeflich, Somasekar Seshagiri

    Published 2009-05-01
    Get full text
    Article
  2. 2
    Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.

    Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. by Jeffrey J Wallin, Jane Guan, Kyle A Edgar, Wei Zhou, Ross Francis, Anthony C Torres, Peter M Haverty, Jeffrey Eastham-Anderson, Sabrina Arena, Alberto Bardelli, Sue Griffin, John E Goodall, Kyla M Grimshaw, Klaus P Hoeflich, Christopher Torrance, Marcia Belvin, Lori S Friedman

    Published 2012-01-01
    Get full text
    Article
  3. 3
    Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

    Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma by Stefanie S. Schalm, Erin O’Hearn, Kevin Wilson, Timothy P. LaBranche, Grace Silva, Zhuo Zhang, Lucian DiPietro, Neil Bifulco, Richard Woessner, Nicolas Stransky, Darshan Sappal, Robert Campbell, Riadh Lobbardi, Michael Palmer, Joseph Kim, Chaoyang Ye, Marion Dorsch, Christoph Lengauer, Timothy Guzi, Vivek Kadambi, Andrew Garner, Klaus P. Hoeflich

    Published 2023-01-01
    Get full text
    Article

Search Tools: